Arcutis appoints John Smither as interim CFO with $550K salary, option grant of 125K shares at $8.54

Arcutis Biotherapeutics, Inc.

Base salary of $550,000 and target annual bonus of 45% of base salary.
Option to purchase 125,000 shares at $8.54 per share, vesting 2.0833% monthly.
Severance provides up to 12 months base salary and bonus, plus COBRA reimbursement, upon qualifying termination during change in control.
Equity awards accelerate 100% upon qualifying termination during change in control period; performance awards vest at greater of target or actual.
Employment effective August 31, 2023; Smither reports to CEO and serves as principal financial and accounting officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

John Smither

interim chief financial officer

ARQT · Arcutis Biotherapeutics, Inc.

Effective: 2023-08-31
Filed: September 7, 2023, 7:59 PM ET

announcing the appointment of John Smither as the Company’s interim chief financial officer, effective as of August 31, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..

Action: appointed
Role: interim chief financial officer

Exact text from the filing

announcing the appointment of John Smither as the Company’s interim chief financial officer, effective as of August 31, 2023

View on SEC.gov

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001787306-23-000090

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.